Analyzing the Role of Checkpoint Inhibitors for the Treatment of Melanoma
Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Ryan J. Sullivan, MD, assistant professor of medicine, Harvard Medical School, assistant professor of hematology/oncology, Massachusetts General Hospital, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
Over the last decade, patients with both adjuvant and metastatic melanoma have had limited options until the last decade when immune checkpoint inhibitors were introduced to this space, says Sullivan. These advances include the approval of ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda), among others.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
